Dietary Fiber for Fecal Incontinence

May 8, 2023 updated by: University of Minnesota

The Impact of Fiber Fermentation on Fecal Incontinence

The primary aim of this study was to compare the effects of supplementation with one of three dietary fibers (gum arabic, carboxy-methylcellulose, or psyllium) or a placebo on fecal incontinence (FI), symptom intolerance, and quality of life in community-living individuals who have incontinence of loose or liquid feces. A secondary aim was to explore the possible mechanism(s) underlying the supplements' efficacy (i.e., improvements in stool consistency, water-holding capacity or gel formation).

Study Overview

Study Type

Interventional

Enrollment (Actual)

206

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • University of Minnesota

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • age ≥18 years
  • living in the community (not a nursing home or assisted living facility)
  • self-report of usually having FI of loose or liquid consistency at least twice in a 2-wk period
  • toilets independently
  • ability to read and write in English.
  • Persons that regularly performed pelvic floor muscle exercises and/or biofeedback on a maintenance regimen for at least 20 wks or who took a steady dose of anti-motility medications on a regular schedule that still met the FI criteria were also eligible.

Exclusion Criteria:

  • difficulty swallowing,
  • a gastrointestinal (GI) tract altered by surgery,
  • a malabsorption disorder,
  • inflammatory bowel disease,
  • gastrointestinal cancer or active cancer treatment,
  • allergy to the fibers,
  • regularly used a laxative or enema, were tube-fed, or unwilling to discontinue taking periodic self-prescribed fiber supplements or anti-diarrheal medications.
  • a score ≤24 on the Mini Mental State Examination
  • having/reporting fewer than two episodes of FI or being incapable of performing study procedures during the run-in baseline period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo

basic recipe for juice and muffin recipe

abbreviated PLB

Experimental: Carboxymethylcellulose

The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.

abbreviated CMC

dietary fiber
Experimental: Gum Arabic

The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.

abbreviated GA

Gum acacia dietary fiber
Other Names:
  • Gum acacia
Experimental: Psyllium

The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.

abbreviated as PSY

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
self-report of an incontinent episode on a daily stool diary
the date and time of an incontinence episode was reported and the ratio of the number of incontinence episodes to total stools daily was calculated

Secondary Outcome Measures

Outcome Measure
Measure Description
self-report of gastro-intestinal symptoms on a daily symptom record

The amount of GI symptoms reported were flatus, belching, bloating, abdominal cramping, nausea, a feeling of fullness, and stomach upset using a categorical scale. Number of times of flatus was also reported.

The amount of two obfuscating symptoms were also reported. headache and sleepiness.

How upsetting/bothersome the symptoms were were also reported.

self-report of quality of life
The Fecal Incontinence Quality of Life tool (FIQL) was used; Rockwood, T.H. et al. Diseases of the Colon & Rectum. 2000;43(1):9-16.
Water-holding capacity of non-frozen of stools
Measure was done on stools of 52 randomly selected subjects (13 from each group) Established method of Wenzl, H. et al. Gastroenterology. 1995;108(6):1729-38 used.
Gel formation of non-frozen stools
Measure was done on stools of 52 randomly selected subjects (13 from each group); Established method of Fischer, M.H. et al.Carbohydrate Research 2004;339(11): 2009-2017.
Total dietary fiber content of feces

Measured in composites of all stools from baseline and supplement periods and non-frozen stools

Established method of Theander O, et al. J AOAC Int. 1995;78(4):1030-44 used.

Self-report of amount of supplement consumed
reported by fractions on supplement intake form and return of unconsumed portion was assessed by study team
amount of fecal incontinence
subjects self-reported greatest amount of soiling (from soling of tissue between buttocks to shoes or floor)
wet and dry weights of collected stools and percentage of water content
collected stools were weighed and freeze-dried to constant weight; percentage of water content was calculated from these values

Other Outcome Measures

Outcome Measure
Measure Description
self-reported rating of consistency of continent stools on a daily stool diary
the Stool Consistency Classification System used was shown to be valid and reliable
usual diet intake
written record of all food and drink consumed
report of additional fluid intake
subjects checked whether the drank required amount of additional fluid and wrote the date and time of drinking
absorbent pad soiling
subjects indicated number of absorbent products that were soiled on stool diary and and saved and returned them to be assessed by study team
self-report of any stools not collected
reported on stool diary daily with reason for not collecting
Stool Color change
date and time a stool color change was observed after swallowing a capsule with a decoy or marker dose of a food dye; date and time capsule was taken was also reported
in vitro fiber degradation
nested experiment of in vitro degradation of each dietary fiber by stools of subjects using established procedure reported in Bliss, D.Z. et al. Nurs. Res. 2001, 50, 203-213.
total dietary fiber content of fiber sources used in Study
established method of Theander O. et al. J AOAC Int. 1995;78(4):1030-44 used.
Personal Goals of Treatment for Fecal Incontinence and Satisfaction with Achievement of Goals
data obtained by semi-structured interview
modifications of preparation of foods, diet intake, and eating pattern to manage fecal incontinence
data obtained by semi-structured interview

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Donna Z Bliss, phD, University of Minnesota

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2004

Primary Completion (Actual)

June 1, 2007

Study Completion (Actual)

December 1, 2010

Study Registration Dates

First Submitted

November 21, 2012

First Submitted That Met QC Criteria

November 27, 2012

First Posted (Estimate)

November 30, 2012

Study Record Updates

Last Update Posted (Actual)

May 9, 2023

Last Update Submitted That Met QC Criteria

May 8, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fecal Incontinence

Clinical Trials on Placebo

3
Subscribe